Sarepta Therapeutics Announces Favorable Safety Results From Phase I Clinical Study Of Influenza Drug Candidate
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company’s lead candidate for the treatment of influenza virus, in healthy volunteers. The clinical trial is being conducted at the National Institutes of Health (NIH) through a collaboration between the company and the NIH’s National Institute of Allergy and Infectious Diseases. AVI-7100 uses Sarepta’s advanced and proprietary PMOplus™ chemistry, which is also the basis of the company’s clinical-stage Ebola and Marburg drug candidates.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.